 |
 |
|
|
RESÚMENES OCTUBRE 2004 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Post-stress
changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of
chronic administration of olanzapine
Can Luo, Haiyun Xu
and Xin-Min Li
Quetiapine
serum concentrations in psychiatric patients: the influence of comedication.
Hasselstrom J, Linnet K.
Ther Drug Monit. 2004 Oct;26(5):486-91
Interaction of
COMT Val108/158 Met Genotype and Olanzapine Treatment on Prefrontal
Cortical Function in Patients With Schizophrenia
Alessandro Bertolino, Grazia Caforio, Giuseppe Blasi, Mariapia De
Candia, Valeria Latorre, Vittoria Petruzzella, Mario Altamura, Gaetano Nappi,
Sergio Papa, Joseph H. Callicott, Venkata S. Mattay, Antonello Bellomo, Tommaso
Scarabino, Daniel R. Weinberger, and Marcello Nardini
Am J Psychiatry 161:1798-1805, October 2004
Lawrence E. Adler, Ann Olincy, Ellen M. Cawthra, Kara A. McRae, Josette
G. Harris, Herbert T. Nagamoto, Merilyne C. Waldo, Mei-Hua Hall, Amanda Bowles,
Laurie Woodward, Randal G. Ross, and Robert Freedman
Am J Psychiatry 161:1822-1828, October 2004
Reduced Basal Ganglia Volumes After Switching to Olanzapine in Chronically Treated Patients With Schizophrenia
Donna J. Lang, Lili C. Kopala, Robert A. Vandorpe, Qing Rui, Geoffrey
N. Smith, Vina M. Goghari, Jocelyne S. Lapointe, and William G. Honer
Am J Psychiatry 161:1829-1836, October 2004
Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder
George M. Simpson, Ira D. Glick, Peter J. Weiden, Steven J. Romano, and
Cynthia O. Siu
Am J Psychiatry
161:1837-1847, October 2004
Association
of Genetic Risks for Schizophrenia and Bipolar Disorder With Specific and
Generic Brain Structural Endophenotypes
Colm
McDonald, Edward T. Bullmore, Pak C. Sham, Xavier Chitnis, Harvey Wickham,
Elvira Bramon, Robin M. Murray
Arch Gen Psychiatry. 2004;61:974-984
Summer Birth and Deficit Schizophrenia. A Pooled Analysis
From 6 Countries
Erick
Messias, Brian Kirkpatrick, Evelyn Bromet, David Ross, Robert W. Buchanan,
William T. Carpenter, Jr, Cenk Tek, Kenneth S. Kendler, Dermot Walsh, Sonia
Dollfus
Arch Gen Psychiatry. 2004;61:985-989
Factors
influencing compulsory admission in first-admitted subjects with psychosis
Audrey Cougnard,
Ester Kalmi, Alain Desage, David Misdrahi, François Abalan,
Hélène Brun-Rousseau, Louis Rachid Salmi and Hélène Verdoux
Social Psychiatry and Psychiatric Epidemiology. Volume
39, Number 10; October 2004: 804 - 809
Ethnicity and
diagnostic patterns in veterans with psychoses
Frederic C. Blow,
John E. Zeber, John F. McCarthy, Marcia Valenstein,
Leah Gillon and C. Raymond Bingham
Social Psychiatry and Psychiatric Epidemiology .Volume
39, Number 10;October 2004: 841 - 851
Localized volume
reduction in prefrontal, temporolimbic, and paralimbic regions in
schizophrenia: an MRI parcellation study
Hidenori Yamasue,
Akira Iwanami, Yoshio Hirayasu, Haruyasu Yamada, Osamu Abe, Noriomi Kuroki, Rin
Fukuda, Kazuo Tsujii, Shigeki Aoki, Kuni Ohtomo, Nobumasa Kato and Kiyoto Kasai
Occupancy of
dopamine D2 receptors by the atypical antipsychotic drugs
risperidone and olanzapine: theoretical implications
W. G. Frankle,
R. Gil, E. Hackett, O. Mawlawi, Y. Zea-Ponce, Z. Zhu,
L. D. Kochan, C. Cangiano, M. Slifstein,
J. M. Gorman, M. Laruelle and A. Abi-Dargham
Psychopharmacology 2004; Volume 175, Number
4: 473 - 480
Prescription of
psychotropic drugs to patients with schizophrenia: an Italian national survey
Lorenza Magliano,
Andrea Fiorillo, Manuela Guarneri, Cecilia Marasco,
Corrado De Rosa, Claudio Malangone, Mario Maj and The
National Mental Health Project Working Group
European Journal of Clinical Pharmacology 2004; Volume
60, Number 7: 513 - 522
Efficacy
of quetiapine for the treatment of schizophrenia: a combined analysis of three
placebo-controlled trials.
Buckley PF.
Curr Med Res Opin. 2004 Sep;20(9):1357-63
A
comparison of extrapyramidal symptoms in older outpatients treated with
quetiapine or risperidone.
Mintzer JE, Mullen JA,
Sweitzer DE
Curr Med Res Opin. 2004 Sep;20(9):1483-91
Combined
treatment of quetiapine with haloperidol in animal models of antipsychotic
effect and extrapyramidal side effects: comparison with risperidone and
chlorpromazine
Miho Tada,
Kiyoharu Shirakawa, Nobuya Matsuoka and Seitaro Mutoh
Psychopharmacology 2004; Volume 176, Number
1: 94 - 100
The persistence of
developmental markers in childhood and adolescence and risk for schizophrenic
psychoses in adult life. A 34-year follow-up of the Northern Finland 1966 birth
cohort
Matti Isohanni,
Graham K. Murray, Jari Jokelainen, Tim Croudace and Peter B. Jones
Risk factors for
transition to first episode psychosis among individuals with ‘at-risk mental
states’
Oliver Mason, Mike
Startup, Sean Halpin, Ulrich Schall, Agatha Conrad and Vaughan Carr
Effects
of
Erica J. Duncan,
Sandor Szilagyi, Marion P. Schwartz, Dragana Bugarski-Kirola, Alena Kunzova,
Shobhit Negi, Myrsini Stephanides, Toby R. Efferen, Burt Angrist, Eric Peselow,
June Corwin, Stephen Gonzenbach and John P. Rotrosen
M. Mehmet Haznedar,
Monte S. Buchsbaum, Erin A. Hazlett, Lina Shihabuddin, Antonia New and Larry J.
Siever
Decreased
nonlinear complexity and chaos during sleep in first episode schizophrenia: a
preliminary report
Matcheri S.
Keshavan, J. David Cashmere, Jean Miewald and Vikram Kumar Yeragani
Margriet M.
Sitskoorn, André Aleman, Sjoerd J. H. Ebisch, Melanie C. M. Appels and René S.
Kahn
William S. Kremen,
Larry J. Seidman, Stephen V. Faraone, Rosemary Toomey and Ming T. Tsuang
NR3A NMDA receptor
subunit mRNA expression in schizophrenia, depression and bipolar disorder
Helena T. Mueller
and James H. Meador-Woodruff
Karmen K. Yoder,
Gary D. Hutchins, Evan D. Morris, Allison Brashear, Chunzi Wang and Anantha
Shekhar
Carmit Nadri, Brian
Dean, Elizabeth Scarr and Galila Agam
Hippocampal
5-hydroxytryptamine receptors: abnormalities in postmortem brain from
schizophrenic subjects
Elizabeth Scarr,
Geoffrey Pavey, David Copolov and Brian Dean
A developmental
model for similarities and dissimilarities between schizophrenia and bipolar
disorder
Robin M. Murray,
Pak Sham, Jim Van Os, Jolanta Zanelli, Mary Cannon and Colm McDonald
Cost-effectiveness
analysis of pharmacological treatments in schizophrenia: critical review of
results and methodological issues
Anirban Basu
Adam M. Brickman,
Monte S. Buchsbaum, Lina Shihabuddin, William Byne, Randall E. Newmark, Jesse
Brand, Shabeer Ahmed, Serge A. Mitelman and Erin A. Hazlett
Georg Winterer and
Daniel R. Weinberger
Tracy
L. Schillerstrom, Jason E. Schillerstrom, Sally Taylor
Gen Hosp Psychiatry. Vol 25, Issue 5, Pages 411-414
(September 2004)
Antipsychotic-induced
hyperprolactinaemia : mechanisms, clinical features and management.
Haddad PM, Wieck A
Differential
impairments of facial affect recognition in schizophrenia subtypes and major
depression
Godehard Weniger,
Claudia Lange, Eckart Rüther and Eva Irle
Rivastigmine augmentation in the management of chronic schizophrenia
with comorbid dementia: an open-label study investigating effects on cognition,
behaviour and activities of daily living.
Mendelsohn, Erika; Rosenthal, Michal; Bohiri, Yosef; Werber,
Edith; Kotler, Moshe; Strous, Rael
International Clinical Psychopharmacology.
19(6):319-324, November 2004.
Heart rate variability during sleep in patients with schizophrenia
treated with olanzapine.
Mann, Klaus; Rossbach, Wolfgang; Muller, Matthias J;
Muller-Siecheneder, Florian; Ru, Hagen; Dittmann, Ralf W
International Clinical Psychopharmacology.
19(6):325-330, November 2004.
Insulin Resistance and Increased Leptin Concentrations in
Noncompliant Schizophrenia Patients but Not in Antipsychotic-Naive First-Episode
Schizophrenia Patients
Belén Arranz, Pilar
Rosel, Nicolas Ramírez, Rosa Dueñas, Paloma Fernández, Jose María Sanchez,
Miguel Angel Navarro, and Luis San
J Clin Psychiatry 2004;65:1335-1342
Oliver D. Howes,
Fiona P. Gaughran, Stephanie A. Amiel, Robin M. Murray;and Lyn S. Pilowsky
J Clin Psychiatry 2004;65:1352-1355
Prevalence, Trends, and Factors Associated With
Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients,
1998-2000
Rahul Ganguly,
Jeffrey A. Kotzan, L. Stephen Miller, Klugh Kennedy, and Bradley C. Martin
J Clin Psychiatry 2004;65:1377-1388
Electrocardiogram
and cardiovascular changes in thioridazine and chlorpromazine poisoning
E. M. Strachan,
C. A. Kelly and D. N. Bateman
European Journal of Clinical 2004; Volume 60,
Number 8: 541 - 545
Cerebrospinal Anandamide Levels are Elevated in Acute
Schizophrenia and are Inversely Correlated with Psychotic Symptoms
Andrea Giuffrida, F Markus Leweke,
Christoph W Gerth, Daniela Schreiber, Dagmar Koethe, Johannes Faulhaber,
Joachim Klosterkötter and Daniele Piomelli
Neuropsychopharmacology (2004) 29, 2108-2114
High-frequency
repetitive transcranial magnetic stimulation in schizophrenia: a combined
treatment and neuroimaging study
G. HAJAK,
J. MARIENHAGEN, B. LANGGUTH, S. WERNER, H. BINDER and
P. EICHHAMMER
Psychological Medicine (2004), 34:7:1157-1163
Elevation of liver
enzyme levels during psychopharmacological treatment is associated with weight
gain
Hubertus Himmerich,
Christian Kaufmann, Andreas Schuld and Thomas Pollmächer
B. Lowyck, M. De
Hert, E. Peeters, M. Wampers, P. Gilis and J. Peuskens
Christoph Lauber,
Marion Anthony, Vladeta Ajdacic-Gross and Wulf Rössler
Impact of present
and past antipsychotic side effects on attitude toward typical antipsychotic
treatment and adherence
M. Lambert, P.
Conus, P. Eide, R. Mass, A. Karow, S. Moritz, D. Golks and D. Naber